Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SCN7A | Q01118 | 3/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488117 | 0.89 | RAB9A (0.44) | NPC1RAB9ATP53GAAMAPT | |
| SCHEMBL17488114 | 0.89 | NPC1 (0.45) | NPC1RAB9ATP53GAAMAPT | |
| SCHEMBL18960432 | 0.88 | NPC1 (0.46) | NPC1RAB9ATP53GAAMAPT | |
| SCHEMBL18960442 | 0.87 | NPC1 (0.47) | NPC1RAB9ATP53GAAMAPT | |
| SCHEMBL17488234 | 0.87 | NPC1 (0.48) | NPC1RAB9ATP53GAAMAPT | |
| SCHEMBL17488172 | 0.86 | CYP3A4 (0.54) | NPC1RAB9ACYP3A4 | |
| SCHEMBL18960425 | 0.84 | CYP3A4 (0.50) | NPC1RAB9AMAPTLMNACYP3A4 | |
| SCHEMBL17488239 | 0.83 | OPRM1 (0.47) | NPC1RAB9AGAASCN9ALMNA | |
| SCHEMBL17487343 | 0.83 | NPC1 (0.45) | NPC1RAB9ATP53GAAMAPT | |
| SCHEMBL17488253 | 0.82 | SCN9A (0.46) | SCN7AKCNH2SCN9ASCN10ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | NPC1 2764/4885RAB9A 3982/4885TP53 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.